ArticleJournal of contemporary brachytherapy2026
Volume not the defining metric: Dosimetric benefits of adding supplemental interstitial needles for small volume cervical tumors.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In brachytherapy for cervical cancer, previous data have demonstrated improved local control with adding supplementary interstitial needles for cervical tumors > 30 cm Material and methods: Fifty-seven intracavity/interstitial (IC/IS) patients treated from November 2019 through November 2023 with HR-CTV < 30 cm Results: The median HR-CTV was 19.3 cm Conclusions: These results suggest a significant dosimetric benefit of adding supplementary interstitial needles even for small volume cervical tumors, allowing enhanced dose shaping to improve HR-CTV coverage and achieving EMBRACE II target dosing goals, while maintaining normal tissue sparing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.